论文部分内容阅读
目的:观察DEC与ECF两种新辅助化疗方案对乳腺癌的近期疗效和不良反应。方法:选择2011年6月--2013年6月间到我院收治的Ⅱ-Ⅲ期乳腺癌女性患者93例,按照新辅助化疗方案分为两组,DEC组48例和ECF组43例,其中(1)DEC方案:多西他赛75mg/m2+表柔比星50mg/m2+环磷酰胺500 mg/m2,第一天静脉滴注,1个周期为21d(2)ECF方案:5-氟尿嘧啶500 mg/m2+表柔比星60mg/m2+环磷酰胺600 mg/m2,第一天静脉滴注,1个周期为21d;两个方案均行4个周期,评价两组患者的疗效和不良毒副反应。结果:DEC组OR、p CR较ECF组高(P<0.05)DEC组在血液系统毒性反应和心脏毒性反应高于ECF组(P<0.05),其他胃肠道反应、肝脏毒性、脱发等方面差异无统计学意义(P>0.05)。结论:在Ⅱ-Ⅲ期乳腺癌患者新辅助化疗中,DEC方案的疗效优于ECF方案,在血液系统毒性反应和心脏毒性反应高于ECF方案,但耐受良好。
Objective: To observe the short-term effects and adverse reactions of DEC and ECF neoadjuvant chemotherapy on breast cancer. Methods: Ninety-three women with stage II-III breast cancer admitted to our hospital from June 2011 to June 2013 were divided into two groups according to neoadjuvant chemotherapy regimen, 48 cases in DEC group and 43 cases in ECF group, (1) DEC program: docetaxel 75mg / m2 + epirubicin 50mg / m2 + cyclophosphamide 500 mg / m2, the first day of intravenous infusion, a cycle of 21d (2) ECF program: 5-fluorouracil 500mg / m2 + epirubicin 60mg / m2 + cyclophosphamide 600mg / m2, the first day of intravenous infusion, a cycle of 21d; two programs were 4 cycles to evaluate the efficacy of two groups of patients and adverse drug toxicity side effects. RESULTS: OR and p CR in DEC group were significantly higher than those in ECF group (P <0.05). The toxicity and cardiotoxicity of DEC group were higher than those of ECF group (P <0.05), other gastrointestinal reactions, liver toxicity and hair loss The difference was not statistically significant (P> 0.05). Conclusion: The efficacy of DEC regimen is better than that of ECF regimen in neoadjuvant chemotherapy for patients with stage II-III breast cancer, and the toxicity and cardiotoxicity in the hematological system are higher than those in ECF regimen.